Shares of GSK PLC GSK inched down 0.77% to £13.50 Thursday, on what proved to be an all-around positive trading session for ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

Barré for every million doses given.

GSK PLC GSK shares inched up 0.18% to £13.60 Wednesday, on what proved to be an all-around favorable trading session for the ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a ...

Kotak Strategic Situations India Fund Il, managed by Kotak Alternate Asset Managers Ltd, has made an investment  Rs 940 crore ...

British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...